Sonus Pharmaceuticals to Present Preclinical Data on New Camptothecin Compound at AACR-NCI-EORTC International Cancer Conference.BOTHELL, Wash. -- Sonus Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SNUS SNUS Swedish National Union of Students ) today announced the scheduled presentation of an abstract at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on the application of the Company's TOCOSOL(R) technology to a new camptothecin derivative. Camptothecins are a rapidly growing class of anti-cancer drugs that are currently used in the treatment of colon, lung and ovarian cancers. The AACR-NCI-EORTC conference is being held November 14-18 at the Pennsylvania Convention Center The Pennsylvania Convention Center is a multi-use public facility in Philadelphia, Pennsylvania which is designed to accommodate conventions, exhibitions, conferences and other events. in Philadelphia. Sonus Abstract Presentation: Date and Time: Poster Session A -- Tuesday, November 15; 12:30 P.M. -- 2:30 P.M. EST and 5:30 P.M. -- 7:30 P.M. EST Poster No. A220: Preclinical Results with SN2310 Emulsion Indicate Improved Pharmacokinetic and Pharmacodynamic Profiles Compared to Irinotecan (CPT-11) The abstract will be available on the Company's web site at www.sonuspharma.com following the AACR-NCI-EORTC conference. About Sonus Pharmaceuticals Headquartered near Seattle, Sonus Pharmaceuticals is focused on the development of novel drugs for the oncology market that may offer improved administration, tolerability, safety and effectiveness. The Company's lead product candidate is TOCOSOL Paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); , a new formulation of the widely prescribed anti-cancer drug paclitaxel. Sonus recently announced the signing of a development and commercialization agreement for TOCOSOL Paclitaxel with Schering AG, a worldwide leader in the pharmaceutical industry. TOCOSOL Paclitaxel has shown promising safety and anti-tumor activity in Phase 2 clinical trials in a variety of solid tumors, including breast, lung, ovarian and bladder cancers, and the product is currently in a Phase 3 pivotal study for the potential treatment of metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer. For additional information on Sonus, including news releases, please visit www.sonuspharma.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed on March 23, 2005 and Quarterly Form 10-Qs for 2005, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. may not approve the Company's proposed New Drug Application; risks of successful development of additional drug delivery products; risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities; and risks that the Company will not obtain regulatory clearance of the license agreement with Schering AG under the Hart-Scott-Rodino Antitrust Improvements Act The Hart-Scott-Rodino Antitrust Improvements Act of 1976 (Public Law 94-435, known commonly as the HSR Act) is a set of amendments to the antitrust laws of the United States, principally the Clayton Antitrust Act. The HSR Act was signed into law by President Gerald R. . The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion